

## Originalbeiträge in Fachzeitschriften (peer-reviewed)

**Fabian D**, Wild C. OD07 Disaggregation Of The Costs Of Pharmaceutical Research And Development. International Journal of Technology Assessment in Health Care. 2024;40(S1): S37-S37. doi:10.1017/S0266462324001430

Louise Schmidt, Ozren Sehic, Ursula Theuretzbacher, **Daniel Fabian** & Claudia Wild (2025): 'Piloting a framework for analysing the public contributions to R&D: new antibiotics in focus', Journal of Pharmaceutical Policy and Practice, 18:1, 2449045, DOI: 10.1080/20523211.2024.2449045

Wild C, Sehic O, Schmidt L, & **Fabian, D.** (2024). Public Contributions to R&D of Medical Innovations: a Framework for Analysis. Health policy, 105235. <https://doi.org/https://doi.org/10.1016/j.healthpol.2024.105235>

**Fabian D** & Wild C (2024). Ownership changes in the pharmaceutical industry: Understanding the 2023 Pharma Mergers and Acquisitions Landscape of Europe. (submitted)

**Fabian D**, Sehic O & Wild C (2024). The Origins of Novo Nordisk and Novartis Products: Piloting a Framework to identify the public contributions. (submitted)

Zechmeister-Koss I, Götz G, **Fabian D** & Wild C (2024). The role of health economics within health technology assessment: past, present, and future – an Austrian perspective. International Journal of Technology Assessment in Health Care, 40(1), e51. doi:10.1017/S0266462324000503